Special report: vaccines for the treatment of prostate cancer
BlueCross BlueShield Association
Record ID 32011000009
English
Authors' recommendations:
Other than sipuleucel-T and ProstVAC-VF, other types of vaccines are much less advanced in the types of clinical investigations that have been carried out. These other vaccines still await the initiation and completion of Phase II randomized trials.The prognosis of the current indication of these vaccine products is a median survival between 20 and 30 months. Demonstration of a survival benefit among candidate patients at earlier stages of disease would require much longer periods of study due to the greater baseline prognosis of these patients. However, without such studies, it would be premature to extend the indications for such vaccines (if any are proven to be effective for the current indication).
Details
Project Status:
Completed
Year Published:
2009
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Male
- Prostatic Neoplasms
Contact
Organisation Name:
BlueCross BlueShield Association
Contact Address:
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name:
tec@bcbsa.com
Contact Email:
tec@bcbsa.com
Copyright:
<p>BlueCross BlueShield Association (BCBS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.